de Vries Anke, Roessl Ewald, Kneepkens Esther, Thran Axel, Brendel Bernhard, Martens Gerhard, Proska Roland, Nicolay Klaas, Grüll Holger
From the *Department of Medical Physics, Catharina Hospital; †Department of Biomedical Engineering, Biomedical NMR, Eindhoven University of Technology, Eindhoven, The Netherlands; ‡Philips Research Europe, Hamburg, Germany; and §Philips Research Europe, Eindhoven, The Netherlands.
Invest Radiol. 2015 Apr;50(4):297-304. doi: 10.1097/RLI.0000000000000126.
The objective of this study was to investigate the feasibility and the accuracy of spectral computed tomography (spectral CT) to determine the tissue concentrations and localization of high-attenuation, iodine-based contrast agents in mice. Iodine tissue concentrations determined with spectral CT are compared with concentrations measured with single-photon emission computed tomography (SPECT) and inductively coupled plasma mass spectrometry (ICP-MS).
All animal procedures were performed according to the US National Institutes of Health principles of laboratory animal care and were approved by the ethical review committee of Maastricht, The Netherlands. Healthy Swiss mice (n = 4) were injected with an iodinated emulsion radiolabeled with indium as multimodal contrast agent for CT and SPECT. The CT and SPECT scans were acquired using a dedicated small-animal SPECT/CT system. Subsequently, scans were performed with a preclinical spectral CT scanner equipped with a photon-counting detector and 6 energy threshold levels. Quantitative data analysis of SPECT and spectral CT scans were obtained using 3-dimensional volumes-of-interest drawing methods. The ICP-MS on dissected organs was performed to determine iodine uptake per organ and was compared with the amounts determined from spectral CT and SPECT.
Iodine concentrations obtained with image-processed spectral CT data correlated well with data obtained either with noninvasive SPECT imaging (slope = 0.96, r = 0.75) or with ICP-MS (slope = 0.99, r = 0.89) in tissue samples.
This preclinical proof-of-concept study shows the in vivo quantification of iodine concentrations in tissues using spectral CT. Our multimodal imaging approach with spectral CT and SPECT using radiolabeled iodinated emulsions together with ICP-based quantification allows a direct comparison of all methods. Benchmarked against ICP-MS data, spectral CT in the present implementation shows a slight underestimation of organ iodine concentrations compared with SPECT but with a more narrow distribution. This slight deviation is most likely caused by experimental rather than technical issues.
本研究的目的是探讨光谱计算机断层扫描(光谱CT)在确定小鼠体内高衰减碘基造影剂的组织浓度和定位方面的可行性和准确性。将光谱CT测定的碘组织浓度与单光子发射计算机断层扫描(SPECT)和电感耦合等离子体质谱(ICP-MS)测量的浓度进行比较。
所有动物实验均按照美国国立卫生研究院实验室动物护理原则进行,并获得荷兰马斯特里赫特伦理审查委员会的批准。健康的瑞士小鼠(n = 4)被注射了一种用铟放射性标记的碘化乳剂,作为用于CT和SPECT的多模态造影剂。使用专用的小动物SPECT/CT系统进行CT和SPECT扫描。随后,使用配备光子计数探测器和6个能量阈值水平的临床前光谱CT扫描仪进行扫描。使用三维感兴趣体积绘制方法对SPECT和光谱CT扫描进行定量数据分析。对解剖后的器官进行ICP-MS检测,以确定每个器官的碘摄取量,并与光谱CT和SPECT测定的量进行比较。
在组织样本中,经图像处理的光谱CT数据获得的碘浓度与通过非侵入性SPECT成像(斜率 = 0.96,r = 0.75)或ICP-MS(斜率 = 0.99,r = 0.89)获得的数据具有良好的相关性。
这项临床前概念验证研究表明,使用光谱CT可以在体内定量组织中的碘浓度。我们采用光谱CT和SPECT的多模态成像方法,结合放射性标记的碘化乳剂以及基于ICP的定量分析,能够对所有方法进行直接比较。与ICP-MS数据相比,本研究中使用的光谱CT显示,与SPECT相比,器官碘浓度略有低估,但分布更窄。这种轻微偏差很可能是由实验问题而非技术问题导致的。